Use of Donor-derived Cell-free DNA to Inform Tapering of Immunosuppression Therapy in Kidney Transplant Recipients: An Observational Study

Use of Donor-derived Cell-free DNA to Inform Tapering of Immunosuppression Therapy in Kidney Transplant Recipients: An Observational Study

Background. Immunosuppression therapy (IST) is required for allograft survival but can cause significant adverse effects. Donor-derived cell-free DNA (dd-cfDNA) is a validated noninvasive biomarker for active rejection in kidney transplant (KTx). Evidence supporting dd-cfDNA testing use in IST manag...

Full description

Bibliographic Details
Main Authors: George Osuchukwu, MD, Alexa Trevino, CMA, Sarah McCormick, PhD, Navchetan Kaur, PhD, Brittany Prigmore, MSc, Nour Al Haj Baddar, PhD, Michelle S. Bloom, PhD, Zachary Demko, PhD, Philippe Gauthier, MD, MBA
Format: Article
Language:English
Published: Wolters Kluwer 2024-04-01
Series:Transplantation Direct
Online Access:http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001610

Internet

http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001610

Similar Items